Ardeypharm

Ardeypharm GmbH, an esteemed pharmaceutical enterprise based in Herdecke, Germany, was established in 1992 with a mission to improve the well-being of patients all around the world. The company specializes in creating and promoting innovative medications and nutraceuticals that focus primarily on treating gastrointestinal and metabolic conditions. Ardeypharm GmbH aims to provide thorough, effective solutions that significantly enhance the quality of life of patients who suffer from these ailments.

Ardeypharm's products are based on the groundbreaking discovery of Dr. Alfred Nissle, a German physician and bacteriologist who, during World War I, realized that a fellow soldier remained unscathed despite an outbreak of dysentery that affected his unit. Upon inspecting the soldier's digestive system, Dr. Nissle discovered E. coli strain Nissle 1917, a non-pathogenic bacteria strain that promotes gut health and prevention of gastrointestinal disorders by supporting natural intestinal flora.

Ardeypharm's offerings include Mutaflor®, a probiotic that contains the live, non-pathogenic E. coli strain Nissle 1917, designed to support natural intestinal flora and promote gut health. The company also provides a liquid formulation of E. coli strain Nissle 1917 known as Mutaflor Suspension®, which is appropriate for children and adults who find capsules difficult to swallow or require lower dosages. Additionally, a lower-dosage form of Mutaflor capsules, called Mutaflor mite®, is available for patients who need a gradual introduction to the probiotic or specific dosages.

Ardeypharm GmbH remains committed to Dr. Nissle's pioneering research by investing in state-of-the-art research and development to further advance the knowledge of gut health and offer cutting-edge solutions to patients worldwide.